Duchenne Muscular Dystrophy (DMD) is a severe genetic disorder characterized by progressive muscle degeneration and weakness. For families carrying the genetic mutation responsible for DMD, the journey to parenthood often involves significant concern regarding the transmission of the condition to the next generation. Fortunately, advancements in reproductive medicine, specifically IVF with PGT-M (Preimplantation Genetic Testing for Monogenic diseases), now offer a reliable path to prevent the transmission of DMD.
In Istanbul, Turkey, our clinic specializes in combining cutting-edge genetic screening with world-class fertility treatments to help families build a healthy future.
Understanding DMD and Its Genetic Basis
DMD is caused by an absence of dystrophin, a protein that helps keep muscle cells intact. It is an X-linked recessive inheritance disorder, meaning the gene is located on the X chromosome. While it primarily affects males, females can be "carriers" of the mutation. A female carrier has a 50% chance of passing the affected X chromosome to her children. Sons who inherit the mutation will develop the disease, while daughters who inherit it will become carriers themselves.
Because of this clear genetic pathway, DMD is an ideal candidate for PGT-M testing during an IVF cycle.
How IVF with PGT-M Prevents DMD Transmission
The primary goal of IVF with PGT-M is to identify embryos that do not carry the DMD mutation before they are transferred to the uterus. This process involves several sophisticated steps:
1. Ovarian Stimulation and Egg Retrieval
The process begins like a standard IVF treatment. The mother undergoes hormonal stimulation to produce multiple eggs, which are then retrieved under light sedation.
2. Fertilization and Embryo Development
The retrieved eggs are fertilized with the father’s (or donor’s) sperm using Intracytoplasmic Sperm Injection (ICSI). The resulting embryos are cultured in our laboratory for five to six days until they reach the blastocyst stage.
3. Embryo Biopsy
Once the embryos reach the blastocyst stage, a few cells are carefully removed from the trophectoderm (the part that becomes the placenta). This procedure does not harm the inner cell mass that develops into the fetus.
4. Genetic Analysis (PGT-M)
The biopsied cells are sent to our specialized genetics lab. Using the family's specific genetic "map," scientists search for the DMD mutation. This allows us to distinguish between embryos that are affected, those that are carriers, and those that are entirely free of the mutation.
5. Embryo Transfer
Only embryos identified as unaffected (or carriers, depending on the parents' choice and medical advice) are selected for transfer. This significantly reduces the risk of having a child with Duchenne Muscular Dystrophy.
Why Choose Istanbul for DMD Genetic Screening?
Turkey has emerged as a global leader in reproductive tourism, particularly for complex genetic cases. Patients traveling to Istanbul for DMD prevention benefit from:
- Advanced Genetic Labs: Our facilities utilize the latest NGS (Next-Generation Sequencing) technologies for high-precision PGT-M.
- Expert Staff: Our embryologists and geneticists have extensive experience in single-gene disorder screening.
- Affordable Care: The cost of IVF and PGT-M in Turkey is significantly lower than in the UK, USA, or much of Europe, without compromising on clinical success or safety.
- Comprehensive Support: We provide full coordination for international patients, including preliminary genetic consultations before you even travel.
Success Rates and Considerations
It is important to understand that the success of IVF with PGT-M depends on various individual factors, including the mother’s age, ovarian reserve, and the number of healthy embryos available after genetic screening. While PGT-M is highly accurate, it is not a guarantee of pregnancy. However, it is currently the most effective preventive measure available for at-risk couples.
For more information on the technological differences between screening methods, you may also find our page on PGT-A testing helpful, as these tests are often performed together to ensure the embryo is both genetically healthy and chromosomally balanced.
Frequently Asked Questions
Can PGT-M detect all types of DMD mutations?
Yes, as long as the specific mutation in the family has been identified through prior blood tests (karyotyping or DNA sequencing). We create a customized "probe" for each family to ensure the highest accuracy in detecting that specific DMD gene deletion or duplication.
Does the embryo biopsy damage the baby?
The biopsy is performed at the blastocyst stage on cells destined to become the placenta. When performed by experienced embryologists, the risk to the embryo's development is minimal, and clinical studies have shown no increased risk of birth defects from the biopsy procedure itself.
Is it possible to choose the gender to avoid DMD?
While DMD primarily affects males, modern medicine prefers PGT-M to check for the specific mutation rather than just gender selection. This allows for the transfer of healthy male embryos as well, rather than discarding them based solely on sex. Our team will discuss the ethical and medical protocols regarding this during your consultation.